Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?

Bibliography

• Wolraich ML, McKeown RE, Visser SN, et al. The prevalence of ADHD: its diagnosis and treatment in four school districts across two states. J Atten Disord 2014;18(7):563-75
   PubMed Web of Science ®Google Scholar
• Bloom B, Jones LI, Freeman G. Summary health statistics for U.S. children: National Health Interview Survey, 2012. Vital Health Stat 10 2013(258):1-81
   PubMedGoogle Scholar
• Simon V, Czobor P, Bálint S, et al. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry 2009;194:204-11
   PubMed Web of Science ®Google Scholar
• Catala-Lopez F, Peiro S, Ridao M, et al. Prevalence of attention deficit hyperactivity disorder among children and adolescents in Spain: a systematic review and meta-analysis of epidemiological studies. BMC Psychiatry 2012;12:168
   PubMed Web of Science ®Google Scholar
• Lindemann C, Langner I, Kraut AA, et al. Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit/hyperactivity disorder in Germany. J Child Adolesc Psychopharmacol 2012;22(4):307-14
   PubMed Web of Science ®Google Scholar
• Bianchini R, Postorino V, Grasso R, et al. Prevalence of ADHD in a sample of Italian students: a population-based study. Res Dev Disabil 2013;34(9):2543-50
   PubMed Web of Science ®Google Scholar
• Suren P, Bakken IJ, Lie KK, et al. Differences across counties in the registered prevalence of autism, ADHD, epilepsy and cerebral palsy in Norway. Tidsskr Nor Laegeforen 2013;133(18):1929-34
   PubMedGoogle Scholar
• Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46(7):894-921
   PubMed Web of Science ®Google Scholar
• Hammerness PH. Stimulant pharmacotherapy for adults with ADHD. In: Surman CBH, editor. ADHD in adults: a practical guide to evaluation and management. Humana Press/Springer, New York; 2013
   Google Scholar
• Wilens TE, Prince JB, Spencer TJ, Biederman J. Stimulants and sudden death: what is a physician to do? Pediatrics 2006;118(3):1215-19
   PubMed Web of Science ®Google Scholar
• Din-Dzietham R, Liu Y, Bielo M, Shamsa F. High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. Circulation 2007;116(13):1488-96
   PubMed Web of Science ®Google Scholar
• Williams CL, Hayman LL, Daniels SR, et al. Cardiovascular health in childhood. A statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2002;106:143
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Tomasi D, et al. Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder. J Neurosci 2012;32(3):841-9
   PubMed Web of Science ®Google Scholar
• Wang GJ, Volkow ND, Wigal T, et al. Long-term stimulant treatment affects brain dopamine transporter level in patients with attention deficit hyperactive disorder. PLoS One 2013;8(5):e63023
   PubMed Web of Science ®Google Scholar
• ADHD: clinical practice guideline. American Academy of Pediatrics. Available from: http://pediatrics.aappublications.org/content/128/5/1007.ful [Last accessed 10 January 2015]
   Google Scholar
• Canadian ADHD practice guidelines 2011, The Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). Available from: http://www.caddra.ca/ [Last accessed 10 January 2015]
   Google Scholar
• ADHD guideline. National Institute for Health and Care Excellence (NICE). Available from: http://www.nice.org.uk/guidance/cg72 [Last accessed 10 January 2015]
   Google Scholar
• Nutt DJ, Fone K, Asherson P, et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2007;21(1):10-41
   PubMed Web of Science ®Google Scholar
• Barner JC, Khoza S, Oladapo A. ADHD medication use, adherence, persistence and cost among Texas Medicaid children. Curr Med Res Opin 2011;27(Suppl 2):13-22
   PubMed Web of Science ®Google Scholar
• Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 2010;19(4):353-64
   PubMed Web of Science ®Google Scholar
• Faraone SV. Understanding the effect size of lisdexamfetamine dimesylate for treating ADHD in children and adults. J Atten Disord 2012;16(2):128-37
   PubMed Web of Science ®Google Scholar
• Surman CB, Hammerness PG, Pion K, Faraone SV. Do stimulants improve functioning in adults with ADHD? A review of the literature. Eur Neuropsychopharmacol 2013;23(6):528-33
   PubMed Web of Science ®Google Scholar
• Ballard JE, Boileau RA, Sleator EK, et al. Cardiovascular responses of hyperactive children to methylphenidate. JAMA 1976;236(25):2870-4
   PubMed Web of Science ®Google Scholar
• Safer DJ. Relative cardiovascular safety of psychostimulants used to treat ADHD. J Child Adolesc Psychopharmacol 1992;2(4):279-90
   PubMedGoogle Scholar
• Rapport MD, Moffitt C. ADHD and methylphenidate: a review of height/weight cardiovascular, and somatic complaint side effects. Clin Psychol Rev 2002;22(8):1107-31
   PubMed Web of Science ®Google Scholar
• Vitiello B. Understanding the risk of using medications for ADHD with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am 2008;17(2):459-74
   PubMed Web of Science ®Google Scholar
• Stiefel G, Besag FM. Cardiovascular effects of methylphenidate, amphetamines, and atomoxetine in the treatment of ADHD. Drug Saf 2010;33(10):821-42
   PubMed Web of Science ®Google Scholar
• Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry 2011;50(10):978-90
   PubMed Web of Science ®Google Scholar
• Wilens T, McBurnett K, Stein M, et al. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2005;44(10):1015-23
   PubMed Web of Science ®Google Scholar
• McGough JJ, Biederman J, Wigal SB, et al. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005;44(6):530-8
   PubMed Web of Science ®Google Scholar
• Findling RL, Childress AC, Krishnan S, McGough JJ. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr 2008;13(7):614-20
   PubMed Web of Science ®Google Scholar
• Findling RL, Wigal SB, Bukstein OG, et al. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Clin Ther 2009;31(8):1844-55
   PubMed Web of Science ®Google Scholar
• Bejerot S, Rydén EM, Arlinde CM. Two-year outcome of treatment with central stimulant medication in adult attention-deficit/hyperactivity disorder: a prospective study. J Clin Psychiatry 2010;71(12):1590-7
   PubMed Web of Science ®Google Scholar
• Adler L, Orman C, Starr HL, et al. Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose–titration, 1-year study. J Clin Psychopharmacol 2011;108-14
   PubMed Web of Science ®Google Scholar
• Weisler RH, Biederman J, Spencer TJ, Wilens TE. Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr 2005;10(12 Suppl 20):35-43
   PubMed Web of Science ®Google Scholar
• Stowe CD, Gardner SF, Gist CC. 24-hour ambulatory blood pressure monitoring in male children receiving stimulant therapy. Ann Pharmacother 2002;36(7-8):1142-9
   PubMed Web of Science ®Google Scholar
• Samuels JA, Franco K, Wan F, Sorof JM. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol 2006;21(1):92-5
   PubMed Web of Science ®Google Scholar
• Grisaru S, Yue MW, Mah JC, Hamiwka LA. Ambulatory blood pressure monitoring in a cohort of children referred with suspected hypertension: characteristics of children with and without attention deficit hyperactivity disorder. Int J Hypertens 2013;2013:419208
   PubMedGoogle Scholar
• Donner R, Michaels MA, Ambrosini PJ. Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorder. Biol Psychiatry 2007;61(5):706-12
   PubMed Web of Science ®Google Scholar
• Vitiello B, Elliott GR, Swanson JM, et al. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. Am J Psychiatry 2012;169(2):167-77
   PubMed Web of Science ®Google Scholar
• Vetter VL, Elia J, Erickson C, et al. A scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 2008;117:2407-23
   PubMed Web of Science ®Google Scholar
• Elia J, Vetter VL. Cardiovascular effects of medications for the treatment of attention-deficit hyperactivity disorder: what is known and how should it influence prescribing in children? Paediatr Drugs 2010;12(3):165-75
   PubMedGoogle Scholar
• Smith G. Raine ADHD Study: Long-term outcomes associated with stimulant medication in the treatment of ADHD in children. Government of Western Australia Department of Health. Available from: http://www.health.wa.gov.au/publications/documents/MICADHD_Raine_ADHD_Study_report_022010.pdf
   Google Scholar
• Arcieri R, Germinario EA, Bonati M, et al. Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. J Child Adolesc Psychopharmacol 2012;22(6):423-31
   PubMed Web of Science ®Google Scholar
• Cohen AL, Jhung MA, Budnitz DS. Stimulant medications and ADHD. N Engl J Med 2006;354(21):2294-5
   PubMed Web of Science ®Google Scholar
• Winterstein AG, Gerhard T, Shuster J, et al. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2007;120:e1494-501
   PubMed Web of Science ®Google Scholar
• Winterstein AG, Gerhard T, Shuster J, Saidi A. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Pediatrics 2009;124(1):e75-80
   PubMed Web of Science ®Google Scholar
• Villalba L, Racoosin J. Postmarketing safety review of sudden death during treatment with drugs used to treat ADHD. Food and Drug Admin 2006. Available from: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210b_07_01_safetyreview.pdf. [Last accessed 5 September 2007]
   Google Scholar
• Gelperin K. Studying Cardiovascular Risk with Drug Treatments of ADHD. FDA Office of Drug Safety Division of Drug Risk Evaluation. Feb 9, 2006
   Google Scholar
• Liberthson R. Sudden death from cardiac causes in children and young adults. N Engl J Med 1996;34(16):1039-44
   Google Scholar
• Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 2011;365(20):1896-904
   PubMed Web of Science ®Google Scholar
• Winterstein AG. Cardiovascular safety of stimulants in children: findings from recent population-based cohort studies. Curr Psychiatry Rep 2013;15(8):379
   PubMed Web of Science ®Google Scholar
• Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011;306:2673-83
   PubMed Web of Science ®Google Scholar
• Gould MS, Walsh BT, Munfakh JL, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry 2009;166(9):992-1001
   PubMed Web of Science ®Google Scholar
• FDA Issues Safety Communication about an Ongoing Review of Stimulant Medications Used in Children with ADHD. U.S. Food and Drug Administration. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm166616.htm
   Google Scholar
• Holick CN, Turnbull BR, Jones ME, et al. Atomoxetine and cerebrovascular outcomes in adults. J Clin Psychopharmacol 2009;29:453-60
   PubMed Web of Science ®Google Scholar
• Schelleman H, Bilker WB, Kimmel SE. Methylphenidate and risk of serious cardiovascular events in adults. Am J Psychiatry 2012;169(2):178-85
   PubMed Web of Science ®Google Scholar
• Schelleman H, Bilker WB, Kimmel SE, et al. Amphetamines, atomoxetine and the risk of serious cardiovascular events in adults. PLoS One 2013;8(1):e52991
   PubMedGoogle Scholar
• Dalsgaard S, Kvist AP, Leckman JF, et al. Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study. J Child Adolesc Psychopharmacol 2014;24(6):302-10
   PubMed Web of Science ®Google Scholar
• Yamada DC, Porter AA, Conway JL, et al. Early repair of congenital heart disease associated with increased rate of attention deficit hyperactivity disorder symptoms. Can J Cardiol 2013;29(12):1623-8
   PubMed Web of Science ®Google Scholar
• Gerhard T, Winterstein AG, Olfson M, et al. Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD. Pharmacoepidemiol Drug Saf 2010;19(5):457-64
   PubMed Web of Science ®Google Scholar
• Batra AS, Alexander ME, Silka MJ. Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason. Pediatr Cardiol 2012;33(3):394-401
   PubMed Web of Science ®Google Scholar
• Buchhorn R, Christian W. Ventricular arrhythmias in children with attention deficit disorder-a symptom of autonomic imbalance? Cardiol Young 2014;24(1):120-5
   PubMed Web of Science ®Google Scholar
• Shetty I, Silver ES, Hordof AJ, et al. Ablation of supraventricular tachycardia allows more liberal therapy in some children with attention-deficit-hyperactivity disorder. Pediatr Int 2011;53(5):715-17
   PubMed Web of Science ®Google Scholar
• Hammerness P, Zusman R, Systrom D, et al. A cardiopulmonary study of lisdexamfetamine in adults with attention-deficit/hyperactivity disorder. World J Biol Psychiatry 2013;14(4):299-306
   PubMed Web of Science ®Google Scholar
• Wilens TE, Zusman RM, Hammerness PG, et al. An open-label study of the tolerability of mixed amphetamine salts in adults with attention-deficit/hyperactivity disorder and treated primary essential hypertension. J Clin Psychiatry 2006;67(5):696-702
   PubMed Web of Science ®Google Scholar
• Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19(5):501-10
   PubMed Web of Science ®Google Scholar
• Wilens TE, Youcha S, Lyne A, et al. A Multisite placebo-controlled trial of morning or evening dosed extended-release guanfacine in combination with psychostimulants in children and adolescents with ADHD. Presented at Biological Psychiatry; 20 – 22May 2010; New Orleans, LA
   Google Scholar
• Donnelly C, Bangs M, Trzepacz P, et al. Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2009;48(2):176-85
   PubMed Web of Science ®Google Scholar
• Adler LA, Spencer TJ, Williams DW, et al. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord 2008;12(3):248-53
   PubMed Web of Science ®Google Scholar
• McCarthy S, Cranswick N, Potts L, et al. Mortality associated with ADHD drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf 2009;32(11):1089-96
   PubMed Web of Science ®Google Scholar
• Shahani SA, Evans WN, Mayman GA, Thomas VC. Attention deficit hyperactivity disorder screening electrocardiograms: a community-based perspective. Pediatr Cardiol 2014;35(3):485-9
   PubMed Web of Science ®Google Scholar
• Leslie LK, Cohen JT, Newburger JW, et al. Costs and benefits of targeted screening for causes of sudden cardiac death in children and adolescents. Circulation 2012;125(21):2621-9
   PubMed Web of Science ®Google Scholar
• Denchev P, Kaltman JR, Schoenbaum M, et al. Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder. Circulation 2010;121(11):1329-37
   PubMed Web of Science ®Google Scholar
• McClernon FJ, Kollins SH. ADHD and smoking: from genes to brain to behavior. Ann N Y Acad Sci 2008;1141:131-47
   PubMed Web of Science ®Google Scholar
• Barry CL, Martin A, Busch SH. ADHD medication use following FDA risk warnings. J Ment Health Policy Econ 2012;15(3):119-25
   PubMed Web of Science ®Google Scholar